{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,7,11]],"date-time":"2026-07-11T10:46:32Z","timestamp":1783766792522,"version":"3.55.0"},"reference-count":65,"publisher":"Oxford University Press (OUP)","issue":"60","license":[{"start":{"date-parts":[[2022,12,1]],"date-time":"2022-12-01T00:00:00Z","timestamp":1669852800000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/academic.oup.com\/journals\/pages\/open_access\/funder_policies\/chorus\/standard_publication_model"}],"funder":[{"name":"National Institute of Health (NIH) National Institute on Aging (NIA) Beeson Career Development Award","award":["K76 AG064394"],"award-info":[{"award-number":["K76 AG064394"]}]},{"name":"National Institute of Health (NIH) National Institute on Aging (NIA) Beeson Career Development Award","award":["K76AG064431"],"award-info":[{"award-number":["K76AG064431"]}]},{"name":"Sustainable Interdisciplinary Research Infrastructure"},{"name":"NCI P30 Cancer Center Support Grant Supplement","award":["3P30CA060553-26S2"],"award-info":[{"award-number":["3P30CA060553-26S2"]}]},{"name":"NCI P30 Cancer Center Support Grant Supplement","award":["NIA R33AG059206-03"],"award-info":[{"award-number":["NIA R33AG059206-03"]}]},{"DOI":"10.13039\/100000002","name":"NIH","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100000002","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2022,12,15]]},"abstract":"<jats:title>Abstract<\/jats:title><jats:p>To improve the care of older adults with cancer, the traditional approach to clinical trial design needs to be reconsidered. Older adults are underrepresented in clinical trials with limited or no information on geriatric-specific factors, such as cognition or comorbidities. To address this knowledge gap and increase relevance of therapeutic clinical trial results to the real-life population, integration of aspects relevant to older adults is needed in oncology clinical trials. Geriatric assessment (GA) is a multidimensional tool comprising validated measures assessing specific health domains that are more frequently affected in older adults, including aspects related to physical function, comorbidity, medication use (polypharmacy), cognitive and psychological status, social support, and nutritional status. There are several mechanisms for incorporating either the full GA or specific GA measures into oncology therapeutic clinical trials to contribute to the overarching goal of the trial. Mechanisms include utilizing GA measures to better characterize the trial population, define trial eligibility, allocate treatment receipt within the context of the trial, develop predictive models for treatment outcomes, guide supportive care strategies, personalize care delivery, and assess longitudinal changes in GA domains. The objective of this manuscript is to review how GA measures can contribute to the overall goal of a clinical trial, to provide a framework to guide the selection and integration of GA measures into clinical trial design, and ultimately enable accrual of older adults to clinical trials by facilitating the design of trials tailored to older adults treated in clinical practice.<\/jats:p>","DOI":"10.1093\/jncimonographs\/lgac021","type":"journal-article","created":{"date-parts":[[2022,12,15]],"date-time":"2022-12-15T22:02:14Z","timestamp":1671141734000},"page":"142-150","source":"Crossref","is-referenced-by-count":15,"title":["Integrating Geriatric Assessment Measures into National Cancer Institute Clinical Trials"],"prefix":"10.1093","volume":"2022","author":[{"given":"Allison","family":"Magnuson","sequence":"first","affiliation":[{"name":"Department of Medicine, University of Rochester Medical Center, Wilmot Cancer Institute , Rochester, NY, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Noam","family":"Van der Walde","sequence":"additional","affiliation":[{"name":"Department of Radiation Oncology, West Cancer Center and Research Institute, University of Tennessee Health Science Center , Germantown, TN, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"June M","family":"McKoy","sequence":"additional","affiliation":[{"name":"Robert H. Lurie Comprehensive Cancer Center, Northwestern University Feinberg School of Medicine , Chicago, IL, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Tanya M","family":"Wildes","sequence":"additional","affiliation":[{"name":"Division of Hematology and Oncology, Department of Internal Medicine, University of Nebraska Medical Center, Nebraska Medicine , Omaha, NE, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Melisa L","family":"Wong","sequence":"additional","affiliation":[{"name":"Divisions of Hematology and Oncology and Geriatrics, Department of Internal Medicine, Helen Diller Family Comprehensive Cancer Center, University of California, San Francisco , San Francisco, CA, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jennifer","family":"Le-Rademacher","sequence":"additional","affiliation":[{"name":"Department of Quantitative Health Sciences, Mayo Clinic , Rochester, MN, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Richard F","family":"Little","sequence":"additional","affiliation":[{"name":"Division of Cancer Treatment and Diagnosis, National Cancer Institute , Bethesda, MD, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-6262-1123","authenticated-orcid":false,"given":"Heidi D","family":"Klepin","sequence":"additional","affiliation":[{"name":"Department of Medicine, Wake Forest School of Medicine , Winston-Salem, NC, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"286","published-online":{"date-parts":[[2022,12,15]]},"reference":[{"issue":"19","key":"2023022317590174400_","doi-asserted-by":"crossref","first-page":"2150","DOI":"10.1200\/JCO.21.00195","article-title":"Understanding treatment tolerability in older adults with cancer","volume":"39","author":"Flannery","year":"2021","journal-title":"J Clin Oncol"},{"issue":"1","key":"2023022317590174400_","doi-asserted-by":"crossref","first-page":"88","DOI":"10.1001\/jamaoncol.2014.161","article-title":"Disparities by race, age, and sex in the improvement of survival for major cancers: results from the National Cancer Institute Surveillance, Epidemiology, and End Results (SEER) Program in the United States, 1990 to 2010","volume":"1","author":"Zeng","year":"2015","journal-title":"JAMA Oncol"},{"issue":"17","key":"2023022317590174400_","doi-asserted-by":"crossref","first-page":"2036","DOI":"10.1200\/JCO.2012.41.6727","article-title":"Under-representation of older adults in cancer registration trials: known problem, little progress","volume":"30","author":"Scher","year":"2012","journal-title":"J Clin Oncol"},{"issue":"22","key":"2023022317590174400_","doi-asserted-by":"crossref","first-page":"4626","DOI":"10.1200\/JCO.2004.02.175","article-title":"Enrollment of elderly patients in clinical trials for cancer drug registration: a 7-year experience by the US Food and Drug Administration","volume":"22","author":"Talarico","year":"2004","journal-title":"J Clin Oncol"},{"issue":"suppl 15","key":"2023022317590174400_","doi-asserted-by":"crossref","first-page":"10009","DOI":"10.1200\/JCO.2017.35.15_suppl.10009","article-title":"FDA analysis of enrollment of older adults in clinical trials for cancer drug registration: a 10-year experience by the US Food and Drug Administration","volume":"35","author":"Singh","year":"2017","journal-title":"J Clin Oncol"},{"issue":"9","key":"2023022317590174400_","doi-asserted-by":"publisher","first-page":"1006","DOI":"10.6004\/jnccn.2021.0043","article-title":"NCCN Guidelines\u00ae Insights: Older Adult Oncology, Version 1.2021","volume":"19","author":"Dotan","year":"2021","journal-title":"J Natl Compr Canc Netw"},{"issue":"22","key":"2023022317590174400_","doi-asserted-by":"publisher","first-page":"2326","DOI":"10.1200\/jco.2018.78.8687","article-title":"Practical assessment and management of vulnerabilities in older patients receiving chemotherapy: ASCO Guideline for Geriatric Oncology","volume":"36","author":"Mohile","year":"2018","journal-title":"J Clin Oncol"},{"issue":"17","key":"2023022317590174400_","doi-asserted-by":"crossref","first-page":"2745","DOI":"10.1200\/JCO.2009.22.4352","article-title":"Providing cancer care to a graying and diverse cancer population in the 21st century: are we prepared?","volume":"27","author":"McKoy","year":"2009","journal-title":"J Clin Oncol"},{"issue":"17","key":"2023022317590174400_","doi-asserted-by":"crossref","first-page":"1795","DOI":"10.1001\/jama.2013.280416","article-title":"Improving the quality of cancer care in an aging population: recommendations from an IOM report","volume":"310","author":"Hurria","year":"2013","journal-title":"JAMA"},{"issue":"32","key":"2023022317590174400_","doi-asserted-by":"crossref","first-page":"3826","DOI":"10.1200\/JCO.2015.63.0319","article-title":"Improving the evidence base for treating older adults with cancer: American Society of Clinical Oncology statement","volume":"33","author":"Hurria","year":"2015","journal-title":"J Clin Oncol"},{"issue":"3","key":"2023022317590174400_","doi-asserted-by":"crossref","first-page":"275","DOI":"10.1016\/j.leukres.2013.12.018","article-title":"The relevance of geriatric assessments for elderly patients with a haematological malignancy\u2014a systematic review","volume":"38","author":"Hamaker","year":"2014","journal-title":"Leuk Res"},{"issue":"4","key":"2023022317590174400_","doi-asserted-by":"crossref","first-page":"379","DOI":"10.1634\/theoncologist.2014-0247","article-title":"Geriatric assessment-identified deficits in older cancer patients with normal performance status","volume":"20","author":"Jolly","year":"2015","journal-title":"Oncologist"},{"issue":"9","key":"2023022317590174400_","doi-asserted-by":"publisher","first-page":"1998","DOI":"10.1002\/cncr.21422","article-title":"Developing a cancer-specific geriatric assessment: a feasibility study","volume":"104","author":"Hurria","year":"2005","journal-title":"Cancer"},{"issue":"3","key":"2023022317590174400_","doi-asserted-by":"crossref","first-page":"245","DOI":"10.1016\/j.jgo.2014.03.001","article-title":"Feasibility of geriatric assessment in community oncology clinics","volume":"5","author":"Williams","year":"2014","journal-title":"J Geriatr Oncol"},{"issue":"12","key":"2023022317590174400_","doi-asserted-by":"crossref","first-page":"e1025","DOI":"10.1200\/JOP.2016.013136","article-title":"Reliability, validity, and feasibility of a computer-based geriatric assessment for older adults with cancer","volume":"12","author":"Hurria","year":"2016","journal-title":"J Oncol Pract"},{"issue":"10","key":"2023022317590174400_","doi-asserted-by":"crossref","first-page":"1290","DOI":"10.1200\/JCO.2010.30.6985","article-title":"Implementing a geriatric assessment in cooperative group clinical cancer trials: CALGB 360401","volume":"29","author":"Hurria","year":"2011","journal-title":"J Clin Oncol"},{"issue":"25","key":"2023022317590174400_","doi-asserted-by":"publisher","first-page":"3457","DOI":"10.1200\/jco.2011.34.7625","article-title":"Predicting chemotherapy toxicity in older adults with cancer: a prospective multicenter study","volume":"29","author":"Hurria","year":"2011","journal-title":"J Clin Oncol"},{"issue":"6","key":"2023022317590174400_","doi-asserted-by":"crossref","first-page":"608","DOI":"10.1200\/JCO.20.02063","article-title":"Development and validation of a risk tool for predicting severe toxicity in older adults receiving chemotherapy for early-stage breast cancer","volume":"39","author":"Magnuson","year":"2021","journal-title":"J Clin Oncol"},{"issue":"20","key":"2023022317590174400_","doi-asserted-by":"crossref","first-page":"2366","DOI":"10.1200\/JCO.2015.65.4327","article-title":"Validation of a prediction tool for chemotherapy toxicity in older adults with cancer","volume":"34","author":"Hurria","year":"2016","journal-title":"J Clin Oncol"},{"issue":"6","key":"2023022317590174400_","doi-asserted-by":"crossref","first-page":"847","DOI":"10.1016\/j.jgo.2019.04.016","article-title":"A systematic review on the association of the G8 with geriatric assessment, prognosis and course of treatment in older patients with cancer","volume":"10","author":"van Walree","year":"2019","journal-title":"J Geriatr Oncol"},{"issue":"9","key":"2023022317590174400_","doi-asserted-by":"crossref","first-page":"1120","DOI":"10.6004\/jnccn.2015.0137","article-title":"Geriatric assessment-guided care processes for older adults: a Delphi consensus of geriatric oncology experts","volume":"13","author":"Mohile","year":"2015","journal-title":"J Natl Compr Canc Netw"},{"issue":"2","key":"2023022317590174400_","doi-asserted-by":"publisher","first-page":"196","DOI":"10.1001\/jamaoncol.2019.4728","article-title":"Communication with older patients with cancer using geriatric assessment: a cluster-randomized clinical trial from the National Cancer Institute community oncology research program","volume":"6","author":"Mohile","year":"2019","journal-title":"JAMA Oncol"},{"issue":"11","key":"2023022317590174400_","doi-asserted-by":"crossref","first-page":"e214158","DOI":"10.1001\/jamaoncol.2021.4158","article-title":"Geriatric assessment-driven intervention (GAIN) on chemotherapy-related toxic effects in older adults with cancer: a randomized clinical trial","volume":"7","author":"Li","year":"2021","journal-title":"JAMA Oncol"},{"issue":"10314","key":"2023022317590174400_","doi-asserted-by":"publisher","first-page":"1894","DOI":"10.1016\/S0140-6736(21)01789-X","article-title":"Evaluation of geriatric assessment and management on the toxic effects of cancer treatment (GAP70+): a cluster-randomised study","volume":"398","author":"Mohile","year":"2021","journal-title":"Lancet"},{"issue":"2","key":"2023022317590174400_","doi-asserted-by":"crossref","first-page":"494","DOI":"10.1200\/JCO.2002.20.2.494","article-title":"Comprehensive geriatric assessment adds information to Eastern Cooperative Oncology Group performance status in elderly cancer patients: an Italian Group for Geriatric Oncology Study","volume":"20","author":"Repetto","year":"2002","journal-title":"J Clin Oncol"},{"issue":"9779","key":"2023022317590174400_","doi-asserted-by":"publisher","first-page":"1749","DOI":"10.1016\/S0140-6736(11)60399-1","article-title":"Chemotherapy options in elderly and frail patients with metastatic colorectal cancer (MRC FOCUS2): an open-label, randomised factorial trial","volume":"377","author":"Seymour","year":"2011","journal-title":"Lancet"},{"issue":"33","key":"2023022317590174400_","doi-asserted-by":"publisher","first-page":"3753","DOI":"10.1200\/jco.2017.74.4102","article-title":"Modernizing clinical trial eligibility criteria: recommendations of the American Society of Clinical Oncology-Friends of Cancer Research organ dysfunction, prior or concurrent malignancy, and comorbidities working group","volume":"35","author":"Lichtman","year":"2017","journal-title":"J Clin Oncol"},{"issue":"9","key":"2023022317590174400_","doi-asserted-by":"publisher","first-page":"2424","DOI":"10.1158\/1078-0432.Ccr-20-3868","article-title":"Modernizing clinical trial eligibility criteria: recommendations of the ASCO-Friends of Cancer research performance status work group","volume":"27","author":"Magnuson","year":"2021","journal-title":"Clin Cancer Res"},{"key":"2023022317590174400_","doi-asserted-by":"crossref","first-page":"e107","DOI":"10.1200\/EDBK_279513","article-title":"The globalization of geriatric oncology: from data to practice","volume":"40","author":"Kanesvaran","year":"2020","journal-title":"Am Soc Clin Oncol Educ Book"},{"issue":"7","key":"2023022317590174400_","doi-asserted-by":"publisher","first-page":"617","DOI":"10.1056\/NEJMoa2012971","article-title":"Azacitidine and venetoclax in previously untreated acute myeloid leukemia","volume":"383","author":"DiNardo","year":"2020","journal-title":"N Engl J Med"},{"issue":"5","key":"2023022317590174400_","doi-asserted-by":"publisher","first-page":"686","DOI":"10.1001\/jamaoncol.2017.5674","article-title":"Prevalence of cognitive impairment and association with survival among older patients with hematologic cancers","volume":"4","author":"Hshieh","year":"2018","journal-title":"JAMA Oncol"},{"issue":"11","key":"2023022317590174400_","doi-asserted-by":"publisher","first-page":"1214","DOI":"10.1200\/jco.20.02465","article-title":"Simplified geriatric assessment in older patients with diffuse large B-cell lymphoma: the prospective elderly project of the Fondazione Italiana Linfomi","volume":"39","author":"Merli","year":"2021","journal-title":"J Clin Oncol"},{"issue":"13","key":"2023022317590174400_","doi-asserted-by":"publisher","first-page":"3377","DOI":"10.1002\/cncr.26646","article-title":"Predicting the risk of chemotherapy toxicity in older patients: the Chemotherapy Risk Assessment Scale for High-Age Patients (CRASH) score","volume":"118","author":"Extermann","year":"2012","journal-title":"Cancer"},{"issue":"11","key":"2023022317590174400_","doi-asserted-by":"publisher","first-page":"1646","DOI":"10.1182\/blood.2021013671","article-title":"Geriatric assessment predicts non-fatal toxicities and survival for intensively treated older adults with AML","volume":"139","author":"Min","year":"2022","journal-title":"Blood"},{"issue":"13","key":"2023022317590174400_","doi-asserted-by":"publisher","first-page":"1476","DOI":"10.1200\/jco.2015.63.5839","article-title":"Use of a comprehensive geriatric assessment for the management of elderly patients with advanced non-small-cell lung cancer: the phase III randomized ESOGIA-GFPC-GECP 08-02 study","volume":"34","author":"Corre","year":"2016","journal-title":"J Clin Oncol"},{"issue":"33","key":"2023022317590174400_","doi-asserted-by":"crossref","first-page":"4047","DOI":"10.1200\/JCO.2016.67.5926","article-title":"Comprehensive geriatric assessment-guided therapy does improve outcomes of older patients with advanced lung cancer","volume":"34","author":"Gajra","year":"2016","journal-title":"J Clin Oncol"},{"issue":"6","key":"2023022317590174400_","first-page":"e740","article-title":"Predictors of unplanned hospitalizations among older adults receiving cancer chemotherapy","volume":"17","author":"Klepin","year":"2021","journal-title":"J Clin Oncol Pract"},{"issue":"29","key":"2023022317590174400_","doi-asserted-by":"publisher","first-page":"3711","DOI":"10.1200\/jco.2013.49.6125","article-title":"End points and trial design in geriatric oncology research: a joint European organisation for research and treatment of cancer\u2014Alliance for Clinical Trials in Oncology\u2014International Society of Geriatric Oncology position article","volume":"31","author":"Wildiers","year":"2013","journal-title":"J Clin Oncol"},{"issue":"1","key":"2023022317590174400_","doi-asserted-by":"publisher","first-page":"107","DOI":"10.1016\/j.jgo.2019.10.002","article-title":"Geriatric assessment among older adults receiving intensive therapy for acute myeloid leukemia: report of CALGB 361006 (Alliance)","volume":"11","author":"Klepin","year":"2020","journal-title":"J Geriatr Oncol"},{"issue":"13","key":"2023022317590174400_","doi-asserted-by":"publisher","first-page":"2068","DOI":"10.1182\/blood-2014-12-615187","article-title":"Geriatric assessment predicts survival and toxicities in elderly myeloma patients: an International Myeloma Working Group report","volume":"125","author":"Palumbo","year":"2015","journal-title":"Blood"},{"issue":"12","key":"2023022317590174400_","doi-asserted-by":"crossref","first-page":"1691","DOI":"10.1046\/j.1532-5415.2001.49281.x","article-title":"The Vulnerable Elders Survey: a tool for identifying vulnerable older people in the community","volume":"49","author":"Saliba","year":"2001","journal-title":"J Am Geriatr Soc"},{"issue":"8","key":"2023022317590174400_","doi-asserted-by":"crossref","first-page":"2166","DOI":"10.1093\/annonc\/mdr587","article-title":"Screening older cancer patients: first evaluation of the G-8 geriatric screening tool","volume":"23","author":"Bellera","year":"2012","journal-title":"Ann Oncol"},{"issue":"4","key":"2023022317590174400_","doi-asserted-by":"publisher","first-page":"374","DOI":"10.1182\/blood.2019000758","article-title":"Gait speed, grip strength and clinical outcomes in older patients with hematologic malignancies","volume":"134","author":"Liu","year":"2019","journal-title":"Blood"},{"issue":"24","key":"2023022317590174400_","doi-asserted-by":"publisher","first-page":"3865","DOI":"10.1002\/cncr.30269","article-title":"Frailty as determined by a comprehensive geriatric assessment-derived deficit-accumulation index in older patients with cancer who receive chemotherapy","volume":"122","author":"Cohen","year":"2016","journal-title":"Cancer"},{"issue":"3","key":"2023022317590174400_","doi-asserted-by":"crossref","first-page":"M146","DOI":"10.1093\/gerona\/56.3.M146","article-title":"Frailty in older adults: evidence for a phenotype","volume":"56","author":"Fried","year":"2001","journal-title":"J Gerontol A Biol Sci Med Sci"},{"issue":"7","key":"2023022317590174400_","doi-asserted-by":"crossref","first-page":"722","DOI":"10.1093\/gerona\/62.7.722","article-title":"Frailty in relation to the accumulation of deficits","volume":"62","author":"Rockwood","year":"2007","journal-title":"J Gerontol Ser A Biol Sci Medical Sci"},{"issue":"1","key":"2023022317590174400_","doi-asserted-by":"publisher","first-page":"48","DOI":"10.1016\/j.jgo.2018.06.007","article-title":"Frailty assessment predicts toxicity during first cycle chemotherapy for advanced lung cancer regardless of chronologic age","volume":"10","author":"Ruiz","year":"2019","journal-title":"J Geriatr Oncol"},{"key":"2023022317590174400_","doi-asserted-by":"publisher","first-page":"117","DOI":"10.1200\/cci.19.00094","article-title":"Frailty in older adults with multiple myeloma: a study of US veterans","volume":"4","author":"Patel","year":"2020","journal-title":"J Clin Oncol Clin Cancer Inform"},{"issue":"26","key":"2023022317590174400_","doi-asserted-by":"crossref","first-page":"2517","DOI":"10.1056\/NEJMoa1812836","article-title":"Ibrutinib regimens versus chemoimmunotherapy in older patients with untreated CLL","volume":"379","author":"Woyach","year":"2018","journal-title":"N Engl J Med"},{"issue":"7","key":"2023022317590174400_","doi-asserted-by":"crossref","first-page":"1085","DOI":"10.1016\/j.jgo.2021.04.009","article-title":"Quality of life and Comprehensive Geriatric Assessment (CGA) in older adults receiving accelerated partial breast irradiation (APBI) using a single fraction of multi-catheter interstitial high-dose rate brachytherapy (MIB). The SiFEBI phase I\/II trial","volume":"12","author":"Boulahssass","year":"2021","journal-title":"J Geriatr Oncol"},{"issue":"suppl 15","key":"2023022317590174400_","doi-asserted-by":"publisher","DOI":"10.1200\/jco.2014.32.15_suppl.tps6099","article-title":"Elderly Head and Neck Cancer (ELAN) study: personalized treatment according to geriatric assessment in patients age 70 or older: first prospective trials in patients with squamous cell cancer of the head and neck (SCCHN) unsuitable for surgery","volume":"32","author":"Guigay","year":"2014","journal-title":"J Clin Oncol"},{"issue":"suppl 5","key":"2023022317590174400_","doi-asserted-by":"crossref","first-page":"v450","DOI":"10.1093\/annonc\/mdz252.002","article-title":"Personalized treatment according to geriatric assessment in first-line recurrent and\/or metastatic (R\/M) head and neck squamous cell cancer (HNSCC) patients aged 70 or over: ELAN (ELderly heAd and Neck cancer) FIT and UNFIT trials","volume":"30","author":"Guigay","year":"2019","journal-title":"Ann Oncol"},{"issue":"3","key":"2023022317590174400_","doi-asserted-by":"publisher","first-page":"182","DOI":"10.1007\/s13670-014-0095-4","article-title":"Models of care in geriatric oncology","volume":"3","author":"Magnuson","year":"2014","journal-title":"Curr Geriatr Rep"},{"issue":"6","key":"2023022317590174400_","doi-asserted-by":"publisher","first-page":"457","DOI":"10.1016\/j.jgo.2016.05.006","article-title":"Impact of geriatric assessment on the management of older adults with head and neck cancer: a pilot study","volume":"7","author":"Neve","year":"2016","journal-title":"J Geriatr Oncol"},{"issue":"7","key":"2023022317590174400_","doi-asserted-by":"publisher","first-page":"894","DOI":"10.6004\/jnccn.2017.0122","article-title":"Frailty index developed from a cancer-specific geriatric assessment and the association with mortality among older adults with cancer","volume":"15","author":"Guerard","year":"2017","journal-title":"J Natl Compr Canc Netw"},{"issue":"2","key":"2023022317590174400_","doi-asserted-by":"publisher","first-page":"667","DOI":"10.1002\/jso.26314","article-title":"Multidimensional Prognostic Index (MPI) score has the major impact on outcome prediction in elderly surgical patients with colorectal cancer: the FRAGIS study","volume":"123","author":"Pata","year":"2021","journal-title":"J Surg Oncol"},{"issue":"2","key":"2023022317590174400_","doi-asserted-by":"crossref","first-page":"156","DOI":"10.1016\/j.critrevonc.2007.11.001","article-title":"Shall we operate? Preoperative assessment in elderly cancer patients (PACE) can help. A SIOG surgical task force prospective study","volume":"65","author":"Audisio","year":"2008","journal-title":"Crit Rev Oncol Hematol"},{"issue":"4","key":"2023022317590174400_","doi-asserted-by":"publisher","first-page":"850","DOI":"10.1016\/j.ijrobp.2016.11.048","article-title":"Geriatric assessment as a predictor of tolerance, quality of life, and outcomes in older patients with head and neck cancers and lung cancers receiving radiation therapy","volume":"98","author":"VanderWalde","year":"2017","journal-title":"Int J Radiat Oncol Biol Phys"},{"issue":"3","key":"2023022317590174400_","doi-asserted-by":"publisher","first-page":"401","DOI":"10.1111\/ecc.12179","article-title":"Serial comprehensive geriatric assessment in elderly head and neck cancer patients undergoing curative radiotherapy identifies evolution of multidimensional health problems and is indicative of quality of life","volume":"23","author":"Pottel","year":"2014","journal-title":"Eur J Cancer Care (Engl)"},{"issue":"4","key":"2023022317590174400_","doi-asserted-by":"crossref","first-page":"189","DOI":"10.1016\/j.suronc.2007.04.009","article-title":"Pre-operative assessment of cancer in the elderly (PACE): a comprehensive assessment of underlying characteristics of elderly cancer patients prior to elective surgery","volume":"15","author":"Pope","year":"2006","journal-title":"Surg Oncol"},{"issue":"5","key":"2023022317590174400_","doi-asserted-by":"crossref","first-page":"1069","DOI":"10.1007\/s00432-015-2088-x","article-title":"Development of an oncological-multidimensional prognostic index (Onco-MPI) for mortality prediction in older cancer patients","volume":"142","author":"Brunello","year":"2016","journal-title":"J Cancer Res Clin Oncol"},{"issue":"4","key":"2023022317590174400_","doi-asserted-by":"crossref","first-page":"M221","DOI":"10.1093\/gerona\/55.4.M221","article-title":"Lower extremity function and subsequent disability: consistency across studies, predictive models, and value of gait speed alone compared with the short physical performance battery","volume":"55","author":"Guralnik","year":"2000","journal-title":"J Gerontol A Biol Sci Med Sci"},{"issue":"21","key":"2023022317590174400_","doi-asserted-by":"publisher","first-page":"4287","DOI":"10.1182\/blood-2012-12-471680","article-title":"Geriatric assessment predicts survival for older adults receiving induction chemotherapy for acute myelogenous leukemia","volume":"121","author":"Klepin","year":"2013","journal-title":"Blood"},{"issue":"3","key":"2023022317590174400_","doi-asserted-by":"crossref","first-page":"314","DOI":"10.1046\/j.1532-5415.2003.51104.x","article-title":"Physical performance measures in the clinical setting","volume":"51","author":"Studenski","year":"2003","journal-title":"J Am Geriatr Soc"},{"issue":"1","key":"2023022317590174400_","doi-asserted-by":"crossref","first-page":"89","DOI":"10.1093\/gerona\/glq167","article-title":"Predictive value of the short physical performance battery following hospitalization in older patients","volume":"66A","author":"Volpato","year":"2011","journal-title":"J Gerontol Ser A Biomed Sci Med Sci"}],"container-title":["JNCI Monographs"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/academic.oup.com\/jncimono\/article-pdf\/2022\/60\/142\/49316835\/lgac021.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"syndication"},{"URL":"https:\/\/academic.oup.com\/jncimono\/article-pdf\/2022\/60\/142\/49316835\/lgac021.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,3,10]],"date-time":"2023-03-10T13:01:57Z","timestamp":1678453317000},"score":1,"resource":{"primary":{"URL":"https:\/\/academic.oup.com\/jncimono\/article\/2022\/60\/142\/6908747"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2022,12,1]]},"references-count":65,"journal-issue":{"issue":"60","published-online":{"date-parts":[[2022,12,15]]},"published-print":{"date-parts":[[2022,12,15]]}},"URL":"https:\/\/doi.org\/10.1093\/jncimonographs\/lgac021","relation":{},"ISSN":["1052-6773","1745-6614"],"issn-type":[{"value":"1052-6773","type":"print"},{"value":"1745-6614","type":"electronic"}],"subject":[],"published-other":{"date-parts":[[2022,12,1]]},"published":{"date-parts":[[2022,12,1]]}}}